Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Biomarker and AI-supported FX06 therapy to prevent progression from mild and moderate to severe stages of COVID-19

Project description

New therapy to prevent illness progression to severe stages in COVID-19 patients

Remdesivir and antibody therapy, common treatments of COVID-19 patients in the first two stages of the illness, does not prevent the progression of the disease and admissions to intensive care units in most cases. The EU-funded COVend multidisciplinary consortium aims to develop a new effective therapy for the clinical management of the COVID-19 disease during mild and moderate stages, preventing the disease progression to severe illness. The developments will advance therapeutic candidate FX06 to technology readiness level 9 through a multicentre phase II/III clinical trial. The project will focus on the influence of COVID-19 on endothelial cells and the protective effect of FX06, using omics technologies and creating new algorithms for data analytics.

Objective

More than 2.7 million hospitalisations of COVID-19-infected patients have occurred in Europe alone since the outbreak of the coronavirus in 2020. An average 14% of those patients with mild or moderate illness develop severe symptoms and are eventually admitted to the Intensive Care Unit (ICU). The most common treatment of patients in the first two stages of the illness, such as remdesivir and antibody therapies, have neither shown the desired effect nor prevented the progression of the disease to severe and critical stages of the illness.

Interventions against SARS-CoV-2 are in high need to prevent admissions to ICUs, and would reduce the burden on patients and their families, clinical staff and the healthcare sector. Additionally, such interventions would help to provide ICU beds for non-Covid patients requiring immediate interventions, such as for heart or cancer surgery, both of which are often in need of planned free ICU beds.

In COVend, our multidsciplinary consortium will deliver a new effective therapy against SARS-CoV-2 for the clinical management of the COVID-19 disease during mild and moderate stages, including for the prevention of disease progression to severe illness. This will be achieved by advancing a promising therapeutic candidate, FX06, from Technology Readiness Level (TRL) 7 to TRL9 through a multi-centre phase II/III clinical trial. COVend will study the influence of COVID-19 on endothelial cells (ECs) and the potential protective effect of FX06, and will apply -omics technologies, generate new algorithms and open-source software to carry out data analytics and modelling, and will develop health economic models to assess the socio-economic benefits and cost effectiveness of the new therapy. The COVend consortium unites expertise from different disciplines, including (cell) biology, ICT expertise for AI-based evaluations, pharma, economics and social sciences, as well as clinical expertise from 13 European countries.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-HLTH-2021-CORONA-01

See all projects funded under this call

Coordinator

JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 1 425 474,03
Address
THEODOR W ADORNO PLATZ 1
60323 Frankfurt Am Main
Germany

See on map

Region
Hessen Darmstadt Frankfurt am Main, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 1 425 474,03

Participants (17)

My booklet 0 0